By Jess Jones A leading firm testing infectious diseases, hVIVO, has reported a record year as it looks to start work on an £80m orderbook in 2024. The London-listed firm said on Tuesday it achieved revenue of £56m for the full 2023 financial year, ahead of market expectations and up 15.5 per cent from the £48.5m it hit in 2022. hVIVO has guided for £63m in 2024 as it starts the year with a strong contracted orderbook of £80m as of the end of December. hVIVO also said it is on track to complete its move to a new clinical trial facility in Canary Wharf in the first half of this year. The plans …